ArticleTransplantation direct2026
Donation After Circulatory Death Islets are Comparable to Standard-of-Care Donation After Brain Death Islets: Analysis of 801 Consecutive Human Islet Isolations.
Article in Transplantation direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transplantation of isolated human islets is a valuable therapy for individuals with severe type 1 diabetes. A shortage of suitable pancreata and islets hinders access to islet transplantation (IT). Organ donation after circulatory death (DCD) islets are believed inferior and not appropriate for clinical IT. We readdressed this and compared outcomes between DCD and standard-of-care donation after brain death (DBD) islets. Methods: The data sample comprised 801 human islet isolations >2 decades from a single IT center. Islets from DCD and DBD donor organs were compared for islet outcome and quality. In some instances, a noninferior equivalency analysis was performed. Results: Across the study interval, islet yield, viability, and function remained high despite a deterioration in donor health biometrics. Noninferior analysis demonstrated that DCD islets were equivalent to DBD islets in islet yield post-culture and in murine diabetes reversion. In fact, in vivo islet function trended to more diabetes reversal in mice receiving DCD islets versus animals given DBD islets (75% versus 67%). As well, no significant differences were observed between groups in age, body mass index, pancreas cold ischemia time, digestion switch time, islet yield (success >250 000 islet equivalent), purity (>80%), recovery (>75%), post-culture viability, transplantable preparations, or insulin stimulation index. The median days of hospitalization and warm ischemia time were significantly greater in DCD versus the DBD group. Predictably, elevated donor hemoglobin A1c negatively impacted islet quality regardless of donation death status. Conclusions: Results from islet isolations >2 decades from a single center are presented. DCD islets were found to be equivalent to DBD islets on several relevant metrics. These findings encourage wider use of DCD donor islets for clinical IT.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.